Advanced Prostate Cancer VL

Using Biomarkers to Determine When Biopsy and When to Repeat the Biopsy- Stephen Williams

Details
In this slide presentation, Stephen Williams details using biomarkers to determine when to biopsy and when to repeat a prostate biopsy specifically: PSA, PHI, 4K, PCA3 and Confirm MDx. He overviews the patient journey pre and post biopsy and the process of determining which patients need a rebiopsy. Biography: Stephen B. Williams, MD Assistant Professor in Urology, Tenure-Track, Robert Earl Cone P...

Active Surveillance: Protecting Patients From Harm- Laurence Klotz

Details
Protecting Patients From Harm - Active Surveillance Biographies: Thomas E Keane Laurence Klotz, MD Related Content: Active Surveillance in PCa+ Active surveillance in prostate cancer: a critical review

IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer- Lorelei Mucci

Details
IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer Biographies: Alicia Morgans, MD, MPH Lorelei Mucci, ScD, MPH Also check out Lorelei Mucci & Philip Kantoff on Outcomes Research and the IRONMAN Project Related Content: Watch: IRONMAN - A Better Understanding of the Variation in Care and Treatment - Daniel George Watch: Lorelei Mucci and Philip Kantoff on O...

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer - Stacy Loeb

Details
(Length of discussion - 17 minutes) Medical or surgical castration are currently the mainstay of therapy for advanced prostate cancer. However, there is controversy regarding the association between testosterone replacement therapy (TRT) and advanced prostate cancer risk. Studies on this have been done in the past and the data was combined in a meta-analysis concluding that there is no increased r...

Non-Controversial Topics in Prostate Cancer - William Oh

Details
William Oh, MD Chief of Division of Hematology and Medical Oncology, Deputy Director of The Tisch Cancer Institute, Professor of Medicine and Urology at Icahn School of Medicine at Mount Sinai in New York Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Debate Position: Optimal Rx for Oligometastatic Disease is Multimodality - Charles Ryan

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Arbiter: Oligometastatic Disease - Robert Bristow

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

An Example With Oligometastatic Prostate Cancer - Bertrand Tombal

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Perspective on Surgery - Borges Dos Reis Rodolfo

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Adjuvant Therapy in High-Risk Prostate Cancer after Radical Prostatectomy - Robert Bristow

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer